Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer

Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer

Abstract Patients with triple-negative breast cancer (TNBC) who have residual disease after neoadjuvant therapy have a high risk of recurrence. We tested the impact of DNA-damaging chemotherapy alone or with PARP inhibition in this high-risk population. Patients with TNBC or deleterious BRCA mutatio...

Full description

Bibliographic Details
Main Authors: Maitri Kalra, Yan Tong, David R. Jones, Tom Walsh, Michael A. Danso, Cynthia X. Ma, Paula Silverman, Mary-Claire King, Sunil S. Badve, Susan M. Perkins, Kathy D. Miller
Format: Article
Language:English
Published: Nature Publishing Group 2021-03-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-021-00240-w

Internet

https://doi.org/10.1038/s41523-021-00240-w

Similar Items